{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:39:45Z","timestamp":1785713985292,"version":"3.56.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020707","name":"Janssen Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13555-024-01274-1","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T19:01:43Z","timestamp":1729018903000},"page":"2999-3015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Factors Affecting Treatment Persistence in Japanese Patients with Psoriasis Prescribed Biologics: A Real-World Study Using an Insurance Claim Database"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0224-563X","authenticated-orcid":false,"given":"Celine","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phiona I-Ching","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"1274_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jdin.2020.10.011","volume":"2","author":"H Goto","year":"2021","unstructured":"Goto H, Nakatani E, Yagi H, et al. Late-onset development of psoriasis in Japan: a population-based cohort study. JAAD Int. 2021;2:51\u201361.","journal-title":"JAAD Int"},{"key":"1274_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8: 743180.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1274_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"LP Vegas","year":"2022","unstructured":"Vegas LP, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database. JAMA Dermatol. 2022;158(5):513\u201322.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1274_CR4","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1111\/1346-8138.16691","volume":"50","author":"H Saeki","year":"2023","unstructured":"Saeki H, Mabuchi T, Asahina A, et al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2023;50(2):e41\u201368.","journal-title":"J Dermatol"},{"issue":"1","key":"1274_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"issue":"5","key":"1274_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/09546634.2017.1398393","volume":"29","author":"DJ No","year":"2018","unstructured":"No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatol Treat. 2018;29(5):460\u20136.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"1274_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/cer-2018-0097","volume":"8","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Pelletier CL, Wilson KL, et al. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. J Comp Eff Res. 2019;8(1):45\u201354.","journal-title":"J Comp Eff Res"},{"issue":"10","key":"1274_CR8","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1080\/03007995.2019.1618805","volume":"35","author":"S Higa","year":"2019","unstructured":"Higa S, Devine B, Patel V, et al. Psoriasis treatment patterns: a retrospective claims study. Curr Med Res Opin. 2019;35(10):1727\u201333.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1274_CR9","first-page":"654","volume":"24","author":"S Lee","year":"2018","unstructured":"Lee S, Xie L, Wang Y, Vaidya N, Baser O. Evaluating the Effect of treatment persistence on the economic burden of moderate to severe psoriasis and\/or psoriatic arthritis patients in the U.S. Department of Defense Population. J Manag Care Spec Pharm. 2018;24(7):654\u201363.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"1274_CR10","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/jcm11061506","volume":"11","author":"E Piragine","year":"2022","unstructured":"Piragine E, Petri D, Martelli A, et al. Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. J Clin Med. 2022;11(6):1506.","journal-title":"J Clin Med"},{"key":"1274_CR11","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s13555-021-00616-7","volume":"11","author":"M Schmitt-Egenolf","year":"2021","unstructured":"Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, et al. Drug persistence of biologic treatments in psoriasis: a Swedish national population study. Dermatol Ther. 2021;11:2107\u201321.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1274_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033486","volume":"7","author":"EA Brezinski","year":"2012","unstructured":"Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS\u00a0One. 2012;7(4): e33486.","journal-title":"PLoS\u00a0One"},{"issue":"6","key":"1274_CR13","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/bjd.12404","volume":"168","author":"K Reich","year":"2013","unstructured":"Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325\u201334.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1274_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.12039","volume":"168","author":"RJ Thorneloe","year":"2013","unstructured":"Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20\u201331.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1274_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","volume":"74","author":"JA Doshi","year":"2016","unstructured":"Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057-65.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1274_CR16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.13611","volume":"30","author":"A Menter","year":"2016","unstructured":"Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148\u201358.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1274_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12895-018-0074-0","volume":"18","author":"R Sruamsiri","year":"2018","unstructured":"Sruamsiri R, Iwasaki K, Tang W, Mahlich J. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018;18(1):5.","journal-title":"BMC Dermatol"},{"issue":"11","key":"1274_CR18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1346-8138.16543","volume":"49","author":"Y Tada","year":"2022","unstructured":"Tada Y, Kim H, Spanopoulos D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study. J Dermatol. 2022;49(11):1106\u201317.","journal-title":"J Dermatol"},{"key":"1274_CR19","unstructured":"JMDC. JMDC Claims Database 2023. Available from: https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/."},{"issue":"1","key":"1274_CR20","doi-asserted-by":"publisher","first-page":"2299598","DOI":"10.1080\/09546634.2023.2299598","volume":"35","author":"C Miyazaki","year":"2024","unstructured":"Miyazaki C, Masuda J, Rodriguez-Rey MD, et al. Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan. J Dermatol Treat. 2024;35(1):2299598.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1274_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/1346-8138.15196","volume":"47","author":"H Saeki","year":"2020","unstructured":"Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201\u201322.","journal-title":"J Dermatol"},{"issue":"5","key":"1274_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","volume":"34","author":"PJ Anderson","year":"2005","unstructured":"Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum. 2005;34(5):19\u201322.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1274_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/1346-8138.15146","volume":"47","author":"M Kishimoto","year":"2020","unstructured":"Kishimoto M, Komine M, Kamiya K, et al. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33\u201340.","journal-title":"J Dermatol"},{"issue":"4","key":"1274_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-023-00910-6","volume":"13","author":"T Fitzgerald","year":"2023","unstructured":"Fitzgerald T, Zhdanava M, Pilon D, et al. Long-term Psoriasis control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA. Dermatol Ther. 2023;13(4):1053\u201368.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1274_CR25","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1080\/09546634.2021.1950600","volume":"33","author":"C Xu","year":"2022","unstructured":"Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a US commercially insured population. J Dermatol Treat. 2022;33(4):2270\u20137.","journal-title":"J Dermatol Treat"},{"key":"1274_CR26","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2147\/CCID.S387759","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Lu J-J, Zhong X-Y, et al. Drug survival outcomes associated with the real-world use of ixekizumab, secukinumab, guselkumab, and adalimumab for the treatment of plaque psoriasis in China: a 52-week single-center retrospective study. Clin Cosmet Investig Dermatol. 2022;15:2245\u201352.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"1274_CR27","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZ Yiu","year":"2022","unstructured":"Yiu ZZ, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131\u201341.","journal-title":"JAMA Dermatol"},{"key":"1274_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","volume":"64","author":"SE Thomas","year":"2024","unstructured":"Thomas SE, Barenbrug L, Hannink G, et al. Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis. Drugs. 2024;64:565\u201378.","journal-title":"Drugs"},{"issue":"3","key":"1274_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13555-023-00893-4","volume":"13","author":"J Hugo","year":"2023","unstructured":"Hugo J, Kojanova M, Turkova B, Gkalpakiotis S. Long-term efficacy, safety, and drug survival of Guselkumab in patients with psoriasis: real-world data from the Czech Republic BIOREP registry. Dermatol Ther (Heidelb). 2023;13(3):787\u2013801.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1274_CR30","doi-asserted-by":"publisher","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","volume":"14","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses\u2013IL PSO (Italian landscape psoriasis). Front Immunol. 2024;14:1341708.","journal-title":"Front Immunol"},{"key":"1274_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22:567\u201379.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"1274_CR32","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1038\/jid.2015.206","volume":"135","author":"A Nast","year":"2015","unstructured":"Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2015;135(11):2641\u20138.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1274_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjd.16809","volume":"180","author":"E Sbidian","year":"2019","unstructured":"Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019;180(1):86\u201393.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1274_CR34","doi-asserted-by":"publisher","first-page":"16068","DOI":"10.1038\/s41598-018-34293-y","volume":"8","author":"PT Lin","year":"2018","unstructured":"Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068.","journal-title":"Sci Rep"},{"issue":"2","key":"1274_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjd.12648","volume":"170","author":"JM van den Reek","year":"2014","unstructured":"van den Reek JM, van L\u00fcmig PP, Driessen RJ, et al. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol. 2014;170(2):415\u201324.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1274_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/jdv.12636","volume":"29","author":"JM van den Reek","year":"2015","unstructured":"van den Reek JM, Tummers M, Zweegers J, et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. J Eur Acad Dermatol Venereol. 2015;29(3):560\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1274_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000010","volume":"8","author":"C Guillet","year":"2022","unstructured":"Guillet C, Seeli C, Nina M, Maul LV, Maul J-T. The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis. Int J Womens Dermatol. 2022;8(2): e010.","journal-title":"Int J Womens Dermatol"},{"issue":"10","key":"1274_CR38","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/jdv.15733","volume":"33","author":"L Van der Schoot","year":"2019","unstructured":"Van der Schoot L, Van den Reek J, Groenewoud J, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019;33(10):1913\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1274_CR39","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3711","volume":"101","author":"CP Hern\u00e1ndez-Fern\u00e1ndez","year":"2021","unstructured":"Hern\u00e1ndez-Fern\u00e1ndez CP, Carretero G, Rivera R, et al. Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort. Acta Derm Venereol. 2021;101(1): adv00354.","journal-title":"Acta Derm Venereol"},{"key":"1274_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2024.100183","volume":"22","author":"K Yadav","year":"2024","unstructured":"Yadav K, Sahu KK, Yadav R, et al. A complex molecular landscape to drug delivery concept for achieving precise therapy in psoriasis. Med Drug Discov. 2024;22: 100183.","journal-title":"Med Drug Discov"},{"issue":"1","key":"1274_CR41","first-page":"77","volume":"3","author":"M Gaylor","year":"2004","unstructured":"Gaylor M, Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol. 2004;3(1):77\u20139.","journal-title":"J Drugs Dermatol"},{"key":"1274_CR42","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/CCID.S407812","volume":"16","author":"M Megna","year":"2023","unstructured":"Megna M, Camela E, Ruggiero A, et al. Use of biological therapies for the management of pustular psoriasis: a new era? Clin Cosmet Investig Dermatol. 2023;16:1677\u201390.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"1274_CR43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/acr.23333","volume":"70","author":"C Ballegaard","year":"2018","unstructured":"Ballegaard C, H\u00f8jgaard P, Dreyer L, et al. Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2018;70(4):592\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"1274_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/ds.ds_51_20","volume":"39","author":"Y Lo","year":"2021","unstructured":"Lo Y, Huang Y-H, Tsai T-F. Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: a bicentric retrospective study. Dermatol Sinica. 2021;39(2):87\u20138.","journal-title":"Dermatol Sinica"},{"issue":"11","key":"1274_CR45","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.ajpath.2015.07.006","volume":"185","author":"G K\u00f5ks","year":"2015","unstructured":"K\u00f5ks G, Uudelepp M-L, Limbach M, et al. Smoking-induced expression of the GPR15 gene indicates its potential role in chronic inflammatory pathologies. Am J Pathol. 2015;185(11):2898\u2013906.","journal-title":"Am J Pathol"},{"issue":"11","key":"1274_CR46","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.3390\/ijms23116130","volume":"23","author":"VS Krishnan","year":"2022","unstructured":"Krishnan VS, K\u00f5ks S. Transcriptional basis of psoriasis from large scale gene expression studies: the importance of moving towards a precision medicine approach. Int J Mol Sci. 2022;23(11):6130.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1274_CR47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/jmedgenet-2019-106283","volume":"57","author":"H Leonard","year":"2020","unstructured":"Leonard H, Blauwendraat C, Krohn L, et al. Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson\u2019s disease. J Med Genet. 2020;57(5):331\u20138.","journal-title":"J Med Genet"},{"issue":"12","key":"1274_CR48","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/mds.27864","volume":"34","author":"S Bandres-Ciga","year":"2019","unstructured":"Bandres-Ciga S, Ahmed S, Sabir MS, et al. The genetic architecture of Parkinson disease in Spain: characterizing population-specific risk, differential haplotype structures, and providing etiologic insight. Mov Disord. 2019;34(12):1851\u201363.","journal-title":"Mov Disord"},{"issue":"9","key":"1274_CR49","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s13555-023-00986-0","volume":"13","author":"A Buja","year":"2023","unstructured":"Buja A, Miatton A, Cozzolino C, et al. The prevalent comorbidome at the onset of psoriasis diagnosis. Dermatol Ther. 2023;13(9):2093\u2013105.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1274_CR50","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s13555-023-00930-2","volume":"13","author":"G Damiani","year":"2023","unstructured":"Damiani G, Amerio P, Bardazzi F, et al. Real-world experience of methotrexate in the treatment of skin diseases: an Italian Delphi consensus. Dermatol Ther. 2023;13(6):1219\u201341.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1274_CR51","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon K, Strober B, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146\u201359.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01274-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01274-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01274-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T15:11:09Z","timestamp":1731510669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01274-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01274-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Celine Miyazaki, Junya Masuda, and Phiona I-Ching Tsai are employees of Janssen Pharmaceutical K.K., Japan and may own stock in Johnson & Johnson. Hidehisa Saeki has received lecture fees from Mitsubishi Tanabe Pharma Corporation, Taiho Pharmaceutical Co., Ltd., Torii Pharmaceutical Co. Ltd., Maruho Co., Ltd., Kyowa Kirin Co., Ltd., AbbVie GK, Novartis Pharma K.K., Eli Lilly Japan K.K., LEO Pharma K.K., Celgene Corp., Janssen Pharmaceutical K.K., and UCB Japan Co. Ltd. and\/or research costs from Maruho Co., Ltd, AbbVie GK, and LEO Pharma K.K; and\/or scholarship donations from Taiho Pharmaceutical Co., Ltd., Maruho Co., Ltd., Eisai Co., Ltd., and Sun Pharma Japan Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All required approvals and permissions for data extraction from the JMDC database and performing pre-specified analyses were obtained. The study used de-identified patient data and was conducted in compliance with all laws and regulations, national guidelines, and other standards regarding the handling of personal information. Informed consent and ethics committee approval were not applicable based on the Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Welfare and Labor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}